Nugenerex Immuno-Oncology Debt 2024

Nugenerex Immuno-Oncology Aktienanalyse

What does Nugenerex Immuno-Oncology do?

Nugenerex Immuno-Oncology Inc is an emerging company in cancer research and treatment. It was founded in 2003 by Dr. William J. Garner and is headquartered in San Diego, California. The origins of Nugenerex Immuno-Oncology lie in the exploration of RNA interference (RNAi) and the development of therapeutics for the treatment of cancer and other diseases. In 2006, the company made a groundbreaking discovery by developing a novel technology called "Blank Gene Therapy," which has the potential to revolutionize cancer treatment. Nugenerex Immuno-Oncology is an innovative biotechnology company focused on developing cancer treatments based on the patient's own immune system. The company has a division for cancer research and development and a division for medical services, combining scientific expertise with a global presence. In its research and development division, Nugenerex Immuno-Oncology focuses on developing novel immunological therapies based on "Blank Gene Therapy." These therapies aim to stimulate the patient's immune system to recognize and destroy cancerous cells. In addition to research and development, the company also offers medical services. The medical services division provides patients and healthcare providers worldwide with access to the latest cancer treatments and clinical trials. By collaborating with doctors and hospitals worldwide, patients gain access to innovative cancer treatments tailored to their specific case. The company has several products in development, including a novel immunotherapeutic called "Enrichin." It is based on "Blank Gene Therapy" and aims to stimulate the patient's immune system to recognize and destroy tumor-like cells. Additionally, the company is working on the development of antibody therapeutics and oncolytic viruses to destroy cancer cells. Nugenerex Immuno-Oncology has also formed a partnership with a leading pharmaceutical company to develop therapeutics for multiple sclerosis and other autoimmune diseases. In summary, Nugenerex Immuno-Oncology is an emerging company in cancer research and treatment, focusing on novel immunological therapies. With its products, services, and global presence, it aims to improve the lives of cancer patients worldwide. Nugenerex Immuno-Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Nugenerex Immuno-Oncology's Debt Structure

Nugenerex Immuno-Oncology's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Nugenerex Immuno-Oncology's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Nugenerex Immuno-Oncology’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Nugenerex Immuno-Oncology’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Nugenerex Immuno-Oncology stock

What is the debt of Nugenerex Immuno-Oncology this year?

Nugenerex Immuno-Oncology has a debt level of 0 USD this year.

What was the debt of Nugenerex Immuno-Oncology compared to the previous year?

The debt of Nugenerex Immuno-Oncology has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in Nugenerex Immuno-Oncology?

High debt can pose a risk for investors of Nugenerex Immuno-Oncology, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Nugenerex Immuno-Oncology?

Low debt means that Nugenerex Immuno-Oncology has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Nugenerex Immuno-Oncology affect the company?

An increase in debt of Nugenerex Immuno-Oncology can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Nugenerex Immuno-Oncology affect the company?

A reduction in debt of Nugenerex Immuno-Oncology can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Nugenerex Immuno-Oncology?

Some factors that can influence the debt of Nugenerex Immuno-Oncology include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Nugenerex Immuno-Oncology so important for investors?

The debts of Nugenerex Immuno-Oncology are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Nugenerex Immuno-Oncology take to change the debt?

To change the debt, Nugenerex Immuno-Oncology can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Nugenerex Immuno-Oncology pay?

Over the past 12 months, Nugenerex Immuno-Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nugenerex Immuno-Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Nugenerex Immuno-Oncology?

The current dividend yield of Nugenerex Immuno-Oncology is .

When does Nugenerex Immuno-Oncology pay dividends?

Nugenerex Immuno-Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nugenerex Immuno-Oncology?

Nugenerex Immuno-Oncology paid dividends every year for the past 0 years.

What is the dividend of Nugenerex Immuno-Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nugenerex Immuno-Oncology located?

Nugenerex Immuno-Oncology is assigned to the '-' sector.

Wann musste ich die Aktien von Nugenerex Immuno-Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nugenerex Immuno-Oncology from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Nugenerex Immuno-Oncology pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Nugenerex Immuno-Oncology in the year 2023?

In the year 2023, Nugenerex Immuno-Oncology distributed 0 USD as dividends.

In which currency does Nugenerex Immuno-Oncology pay out the dividend?

The dividends of Nugenerex Immuno-Oncology are distributed in USD.